{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013415","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.527926+00:00","generated_at":"2026-05-17T06:42:06.854260+00:00","sec_items":["1.01","5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProPhase Labs shareholders approve share increase to 1B and equity plans","bullets":["Shareholders approved increase in authorized common shares from 50M to 1B at Sept 9 special meeting.","Approved amendments to 2022 equity plan and 2025 equity plan, enabling executive participation.","Warrants to CEO Ted Karkus and an investor for 500k shares each now fully exercisable.","Company can now reserve 400% of shares for conversion of July 2025 20% OID notes and warrants.","Bylaw amendment to update principal office address approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013415","json":"https://secwatch.observer/filing/0001493152-25-013415.json","markdown":"https://secwatch.observer/filing/0001493152-25-013415.md","text":"https://secwatch.observer/filing/0001493152-25-013415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315225013415/0001493152-25-013415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315225013415/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:42:06.854260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"621ea5e6439959590bb56bd15a2c967d2a9864be","claim":"ProPhase Labs, Inc.: Updated principal office address to RXR Plaza, Uniondale, New York (effective 2025-09-09).","evidence_excerpt":"stockholders approved an amendment to the Company’s Amended and Restated Bylaws to update the Company’s principal office address to RXR Plaza, Uniondale, New York (Proposal 6).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315225013415/0001493152-25-013415-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-09-09"}],"fact_type":"governance_change"},{"claim_id":"74a8d6c9cb4ab7c436654975eced827ed5ad4361","claim":"ProPhase Labs, Inc.: Increased number of authorized shares of common stock from 50,000,000 to 1,000,000,000 (effective 2025-09-09).","evidence_excerpt":"stockholders also approved Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 1,000,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315225013415/0001493152-25-013415-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-09-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}